Background: The Hospital Outpatient Quality Reporting Program (HOQR) publicly reports measures of US hospitals' use of 4 imaging studies that may be problematic if overused: magnetic resonance imaging (MRI) for low back, follow-up imaging after screening mammography, and abdominal and thoracic computed tomography (CT) with and without contrast.
Objectives: To characterize performance on these measures, determine whether performance was consistent across measures, and identify hospital characteristics associated with highest-decile imaging use.
Research Design: Cross-sectional analysis.
Measurements: Correlation across measures was assessed using Spearman rank order tests. We linked 2008 HOQR data to the 2009 American Hospital Association Survey and used multivariable logistic regression to examine associations between hospital characteristics and the likelihood of highest-decile imaging use.
Results: Imaging use varied widely. Imaging use was weakly correlated (ρ<0.10) across most measures. Compared with hospitals with moderate imaging volume (25th to 75th percentile), hospitals with low volume (<25th percentile) were more likely to report highest-decile imaging use on all measures [adjusted odds ratios (95% confidence interval) range from 1.38 (1.05-1.80) for CT Abdomen to 4.22 (3.04-5.84) for MRI Back]. Rural hospitals were more likely to report highest-decile use on most measures [MRI: 1.42 (1.21-1.68), CT Abdomen: 1.46 (1.28-1.66), and CT Thorax: 1.32 (1.16-1.51)]. For-profit hospitals were more likely to report highest-decile use on mammography [1.47 (1.10-1.98)] and CT Thorax measures [1.71 (1.28-2.27)].
Conclusions: Wide variations in imaging use and extraordinarily high use at some hospitals may indicate that imaging overuse occurs at US hospitals. The effectiveness of the HOQR measures to decrease imaging overuse remains to be seen.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MLR.0b013e31825a8c48 | DOI Listing |
Brain
January 2025
Translational Neuroimaging Laboratory, Montreal Neurological Institute, H3A 2B4, Montreal, Canada.
Plasma phosphorylated tau biomarkers open unprecedented opportunities for identifying carriers of Alzheimer's disease pathophysiology in early disease stages using minimally invasive techniques. Plasma p-tau biomarkers are believed to reflect tau phosphorylation and secretion. However, it remains unclear to what extent the magnitude of plasma p-tau abnormalities reflects neuronal network disturbance in the form of cognitive impairment.
View Article and Find Full Text PDFHepatology
January 2025
AP-HP, Sorbonne Université, Liver Intensive Care Unit, Hepatogastroenterology Department, La Pitié-Salpêtrière Hospital, 47-83 Boulevard de l'Hôpital, Paris 75013, France.
Background And Aims: In cirrhosis, some patients display acute encephalopathy without hyperammonemia (NonHep E) which is not considered as overt hepatic encephalopathy (OHE). We aimed to assess the prevalence and characteristics of NonHep E and OHE in cirrhotic patients displaying acute encephalopathy, assess their respective prognosis and compare it to other causes of acute decompensation (AD) with/without hyperammonemia.
Approach And Results: We conducted a retrolective analysis from a prospective cohort of patients hospitalized for AD.
Background Aims: SBP leads to high rates acute kidney injury (AKI) -hepatorenal syndrome and mortality. Population-based studies on contemporary SBP epidemiology are needed to inform care. In a large, national cohort of patients diagnosed with SBP and confirmed by ascitic fluid criteria, we characterized ascitic fluid characteristics, in-hospital and 12-month mortality, AKI, and recurrent SBP.
View Article and Find Full Text PDFJ Clin Oncol
January 2025
Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of China, Shatin, Hong Kong Special Administrative Region, China.
Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of ex20ins+ advanced/metastatic NSCLC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!